Mechanism of Action: Abraxane
Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) is a microtubule inhibitor.
Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) is a microtubule inhibitor indicated for the treatment of:
- Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
- Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
- Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.
Recent Videos
Related Content
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024Podcast
In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
